Chinese biotech firm Biocytogen raises $65m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically engineered mice for drug testing, has raised RMB410 million ($65 million) in a Series C round of funding led by CMB International Capital, an investment arm of China Merchants Bank.
Existing investors SDIC Venture Capital, a VC arm under the State Development & Investment Corporation (SDIC), 3E Bioventures, Cowin Capital and Oriza Holdings also took part in the round. The company...
More on Greater China
Latest News
HESTA backs PEP-owned Australia software business
HESTA has acquired a A$120 million ($85 million) equity stake in Australian enterprise software and IT services provider Citadel, following its merger with medical practice software specialist Genie Solutions.
CVC exits Malaysia snacks business to Universal Robina
CVC Capital Partners has agreed to sell Malaysia-based snack foods producer Munchy Food Industries to Universal Robina Corporation (URC) – a branded consumer food and beverage business in the Philippines – for MYR1.93 billion ($454 million).
Secondaries supply-demand mismatch most extreme in Asia - AVCJ Forum
There is not enough capital in Asia to address the number of secondary opportunities – mirroring the situation globally – with investors claiming to have more transaction choices than ever before.
China GPU chip designer secures $313m Series A
Moore Threads, a Chinese chip designer established 13 months ago by a team from Nvidia, has closed Series A at RMB2 billion ($313 million) led by Shanghai Guosheng Capital, 5Y Capital, and a BOC International fund.